Showing results (121-130 of 169) with videos related to
Sort By:
Pageof 17
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2021
Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a <i>Post Hoc</i> Analysis of the PRODIGE-GERCOR IDEA-France TrialJulien Taieb, Valérie Taly, Julie Henriques, et al.The Lancet. Oncology|February 11, 2011
Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 studyHedy L Kindler, Tatsuya Ioka, Dirk J Richel, et al.Lung Cancer (Amsterdam, Netherlands)|March 8, 2022
Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO)Benjamin Levy, Fabrice Barlesi, Luis Paz-Ares, et al.Therapeutic Advances in Medical Oncology|January 5, 2023
Predictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trialBernadette de Rauglaudre, Camille Sibertin-Blanc, Aurélie Fabre, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 17, 2020
Frequent Homozygous Deletions of Type I Interferon Genes in Pleural Mesothelioma Confer Sensitivity to Oncolytic Measles VirusTiphaine Delaunay, Carole Achard, Nicolas Boisgerault, et al.Journal for Immunotherapy of Cancer|September 10, 2020
Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor studyClaire F Verschraegen, Guy Jerusalem, Edward F McClay, et al.The Lancet. Oncology|December 3, 2014
Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trialSuresh S Ramalingam, Pasi A Jänne, Tony Mok, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2012
Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancerLuis G Paz-Ares, Bonne Biesma, David Heigener, et al.European Journal of Cancer (Oxford, England : 1990)|May 29, 2018
Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trialsThomas Aparicio, Michel Ducreux, Roger Faroux, et al.Clinical Lung Cancer|June 24, 2014
Oral vinorelbine plus cisplatin as first-line chemotherapy in nonsquamous non-small-cell lung cancer: final results of an International randomized phase II study (NAVotrial 01)Jaafar Bennouna, Libor Havel, Maciej Krzakowski, et al.Pageof 17